Management of Insomnia in Patients with Elevated Liver Enzymes

Medication Recommendations

• The American Academy of Sleep Medicine recommends eszopiclone (Lunesta) as a first-line alternative for insomnia in patients with elevated liver enzymes, with a recommended dose of 2-3 mg at bedtime (1 mg in elderly or hepatic impairment) 1
• The American Academy of Sleep Medicine recommends zolpidem (Ambien) as a first-line alternative for insomnia in patients with elevated liver enzymes, with a recommended dose of 10 mg at bedtime (5 mg in elderly or hepatic impairment) 1, 3
• The American Academy of Sleep Medicine suggests ramelteon (Rozerem) as a second-line option for insomnia in patients with elevated liver enzymes, with a recommended dose of 8 mg at bedtime 1, 3
• The American Academy of Sleep Medicine recommends doxepin (Silenor) as a second-line option for insomnia in patients with elevated liver enzymes, with a recommended dose of 3-6 mg at bedtime 1
• The American Academy of Sleep Medicine suggests avoiding benzodiazepines for chronic insomnia due to risk of dependency, falls, and cognitive impairment 2
• The American Academy of Sleep Medicine recommends against using antihistamines (e.g., diphenhydramine) due to limited efficacy data and anticholinergic side effects 1, 2
• The American Academy of Sleep Medicine warns that kava is associated with acute fatal liver toxicity 2
• The American Academy of Sleep Medicine notes that valerian has limited efficacy data and potential for herb-drug interactions 1
• The American Academy of Sleep Medicine states that melatonin supplements have limited efficacy for insomnia 1

Monitoring and Administration

• Baseline liver function tests should be performed before starting any new sleep medication 1
• Follow-up liver enzymes should be monitored within 2-4 weeks of starting new therapy 1
• Patients should be monitored for signs of hepatotoxicity, including fatigue, nausea, right upper quadrant pain, jaundice, dark urine, or light-colored stools 1
• Dose adjustments should be made based on hepatic function, with lower starting doses and longer intervals between doses for medications with hepatic metabolism 1
• Medications should be taken on an empty stomach to maximize effectiveness 3
• The lowest effective dose should be used for the shortest possible duration 2
• Patients should be counseled on the risks of sleep behaviors (sleepwalking, sleep driving) with BzRAs 2, 3
• Patients should avoid alcohol and other CNS depressants, which can increase the risk of adverse effects 3